rediff.com

NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  

Rediff News  All News 
Rediff.com  » Business » Sun Pharma hit by FDA ban on Gujarat plant, shares fall

Sun Pharma hit by FDA ban on Gujarat plant, shares fall

March 13, 2014 13:22 IST

The US Food and Drug Administration (FDA) has imposed a ban on imports from generic drugmaker Sun Pharmaceutical Industries' plant at Karkhadi in Gujarat, in the latest quality blow for India's drug sector.

Shares in Sun Pharma, India's biggest drugmaker by value, fell as much as 6.4 per cent on Thursday after the FDA's "import alert", which appeared on Wednesday on the agency's website.

An "import alert" results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, according to the FDA website.

A spokesman for Sun was not available for comment.

The Karkhadi plant makes both drug ingredients and formulations, according to Sun's 2013 annual report.

The FDA action against Sun comes amid a rash of regulatory sanctions against Indian generic makers in the last year, triggering concerns about the quality of the medicines supplied by India's $14 billion drug industry to countries including the United States, the biggest market.

The FDA has banned all the India plants of Ranbaxy Laboratories, India's No.1 drugmaker by sales, due to lapses in production quality. Rival Wockhardt has also been barred by regulators from exporting drugs from some of its plants to the United States and the United Kingdom.

India is second only to Canada as a drug exporter to the United States, where it supplies about 40 per cent of generic and over-the-counter drugs.

Image: Founder and Managing Director of Sun Pharmaceuticals.

Photographs: Reuters

Zeba Siddiqui And Sumeet Chatterjee in Mumbai
Source:
© Copyright 2014 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.